Energy Fuels (UUUU) 10-Q 5 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 04, 2022
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-36204
Entity Registrant Name	ENERGY FUELS INC.
Entity Incorporation, State or Country Code	Z4
Entity Tax Identification Number	98-1067994
Entity Address, Address Line One	225 Union Blvd.,
Entity Address, Address Line Two	Suite 600
Entity Address, City or Town	Lakewood,
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80228
City Area Code	303
Local Phone Number	974-2140
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		157,578,374
Amendment Flag	false
Entity Central Index Key	0001385849
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common shares, no par value
Trading Symbol	UUUU
Security Exchange Name	NYSEAMER
TORONTO STOCK EXCHANGE [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common shares, no par value

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues
RE Carbonate	$ 449	$ 0	$ 449	$ 0
Revenues, Vanadium Concentrates	5,295	0	7,707	0
Alternate Feed Materials processing and other	723	456	1,248	809
Total revenues	6,467	456	9,404	809
Costs and expenses applicable to RE Carbonate	222	0	222	0
Costs and expenses applicable to Vanadium concentrates	2,102	0	3,331	0
Underutilized capacity production costs applicable to RE Carbonate	(1,095)	0	(2,758)	0
Total costs and expenses applicable to revenues	3,419	0	6,311	0
Other operating costs
Development, permitting and land holding	1,219	2,517	2,392	5,888
Standby costs	3,323	2,118	6,798	4,253
Accretion of asset retirement obligation	510	351	904	672
Selling costs	21	0	30	0
General and administration	4,682	3,812	9,889	7,185
Total operating loss	(6,707)	(8,342)	(16,920)	(17,189)
Interest expense	(8)	(14)	(17)	(30)
Other loss (Note 12)	(11,344)	(2,435)	(15,852)	(4,482)
Net loss	(18,059)	(10,791)	(32,789)	(21,701)
Items that may be reclassified in the future to profit and loss
Foreign currency translation adjustment	(3,488)	(897)	(1,722)	(544)
Other comprehensive income	(3,488)	(897)	(1,722)	(544)
Comprehensive loss	(21,547)	(11,688)	(34,511)	(22,245)
Net loss	(18,054)	(10,784)	(32,783)	(21,692)
Net loss attributable to:
Net loss	(18,054)	(10,784)	(32,783)	(21,692)
Non-controlling interests	(5)	(7)	(6)	(9)
Owners of the Company	(18,059)	(10,791)	(32,789)	(21,701)
Comprehensive loss attributable to:
Owners of the Company	(21,542)	(11,681)	(34,505)	(22,236)
Non-controlling interests	(5)	(7)	(6)	(9)
Comprehensive loss	$ (21,547)	$ (11,688)	$ (34,511)	$ (22,245)
Basic loss per share (in dollars per share)	$ (0.11)	$ (0.07)	$ (0.21)	$ (0.15)
Diluted loss per share (in dollars per share)	$ (0.11)	$ (0.07)	$ (0.21)	$ (0.15)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 86,363	$ 112,517
Marketable securities (Notes 3 and 15)	11,795	494
Trade and other receivables, net of allowance for credit losses of $223 and $223, respectively	3,019	3,954
Inventories (Note 4)	28,565	30,772
Prepaid expenses and other assets	8,162	1,568
Total current assets	137,904	149,305
Other long-term receivables	1,610	0
Inventories (Note 4)	1,791	1,368
Operating lease right of use asset	271	408
Investments accounted for at fair value (Note 15)	21,302	38,538
Property, plant and equipment, net (Note 5)	21,515	21,983
Mineral properties (Note 5)	83,539	83,539
Restricted cash (Note 6)	20,326	20,305
Total assets	288,258	315,446
Current liabilities
Accounts payable and accrued liabilities (Note 12)	3,284	5,764
Current portion of operating lease liability	312	324
Current portion of asset retirement obligation (Note 6)	219	27
Total current liabilities	3,815	6,115
Operating lease liability	0	145
Asset retirement obligation (Note 6)	13,927	13,660
Total liabilities	17,742	19,920
Equity
Share capital Common shares, without par value, unlimited shares authorized; shares issued and outstanding 157,569,420 at June 30, 2022 and 156,262,199 at December 31, 2021	695,404	685,903
Accumulated deficit	(429,054)	(396,271)
Accumulated other comprehensive income	221	1,943
Total shareholders' equity	266,571	291,575
Non-controlling interests	3,945	3,951
Total equity	270,516	295,526
Total liabilities and equity	288,258	315,446
Commitments and contingencies (Note 13)

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts Receivable, Allowance for Credit Loss, Current	$ 223	$ 223
Common stock, shares, issued (in shares)	157,569,420	156,262,199
Common stock, shares, outstanding (in shares)	157,569,420	156,262,199

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total	Common Stock	Deficit	Accumulated other comprehensive income	Total shareholders' equity	Non-controlling interests
Beginning balance ( in shares) at Dec. 31, 2020		134,311,033
Beginning balance at Dec. 31, 2020	$ 157,546	$ 549,317	$ (397,812)	$ 2,308	$ 153,813	$ 3,733
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(10,910)		(10,908)		(10,908)	(2)
Other comprehensive income	353			353	353
Shares Issued For Cash By At The Market Offering Shares		5,534,166
Shares Issued For Cash By At The Market Offering	30,603	$ 30,603			30,603
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	689	689			689
Share-based compensation	697	$ 697			697
shares issued for exrcise of stock options (in shares)		278,111
Shares issued for the vesting of restricted stock units	666	$ 666			666
Shares issued for the vesting of restricted stock units (in shares)		478,781
Cash paid to fund employee income tax withholding due upon vesting of restricted stock units	(659)	$ (659)			(659)
Shares issued for exercise of warrants (in shares)		190,405
Shares issued for exercise of warrants	1,105	$ 1,105			1,105
Shares issued for consulting services (in shares)		(24,000)
Shares issued for consulting services	(95)	$ (95)			(95)
Ending balance (in shares) at Mar. 31, 2021		140,816,496
Ending balance at Mar. 31, 2021	178,807	$ 581,135	(408,720)	2,661	175,076	3,731
Beginning balance ( in shares) at Dec. 31, 2020		134,311,033
Beginning balance at Dec. 31, 2020	157,546	$ 549,317	(397,812)	2,308	153,813	3,733
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(21,701)
Other comprehensive income	(544)
Ending balance (in shares) at Jun. 30, 2021		148,597,701
Ending balance at Jun. 30, 2021	215,831	$ 629,618	(419,504)	1,764	211,878	3,953
Beginning balance ( in shares) at Mar. 31, 2021		140,816,496
Beginning balance at Mar. 31, 2021	178,807	$ 581,135	(408,720)	2,661	175,076	3,731
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(10,791)		(10,784)		(10,784)	(7)
Other comprehensive income	(897)			(897)	(897)
Shares Issued For Cash By At The Market Offering Shares		6,043,937
Shares Issued For Cash By At The Market Offering	38,040	$ 38,040			38,040
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	855	855			855
Share-based compensation	493	$ 493			493
shares issued for exrcise of stock options (in shares)		251,960
Shares issued for the vesting of restricted stock units	710	$ 710			710
Cash paid to fund employee income tax withholding due upon vesting of restricted stock units	(48)	$ (48)			(48)
Shares issued for exercise of warrants (in shares)		1,474,439
Shares issued for exercise of warrants	10,093	$ 10,093			10,093
Shares issued for consulting services (in shares)		(8,369)
Shares issued for consulting services	$ (50)	$ (50)			(50)
Shares issued for exercise of stock appreciation rights (in shares)	2,500
Contributions attributable to non-controlling interest						229
Ending balance (in shares) at Jun. 30, 2021		148,597,701
Ending balance at Jun. 30, 2021	$ 215,831	$ 629,618	(419,504)	1,764	211,878	3,953
Beginning balance ( in shares) at Dec. 31, 2021		156,262,199
Beginning balance at Dec. 31, 2021	295,526	$ 685,903	(396,271)	1,943	291,575	3,951
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(14,730)		(14,729)		(14,729)	(1)
Other comprehensive income	1,766			1,766	1,766
Shares Issued For Cash By At The Market Offering Shares		413,751
Shares Issued For Cash By At The Market Offering	4,260	$ 4,260			4,260
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	96	96			96
Share-based compensation	862	$ 862			862
shares issued for exrcise of stock options (in shares)		135,926
Shares issued for the vesting of restricted stock units	328	$ 328			328
Shares issued for the vesting of restricted stock units (in shares)		362,350
Cash paid to fund employee income tax withholding due upon vesting of restricted stock units	(884)	$ (884)			(884)
Shares issued for consulting services (in shares)		(6,022)
Shares issued for consulting services	(51)	$ (51)			(51)
Ending balance (in shares) at Mar. 31, 2022		157,180,248
Ending balance at Mar. 31, 2022	287,083	$ 690,424	(411,000)	3,709	283,133	3,950
Beginning balance ( in shares) at Dec. 31, 2021		156,262,199
Beginning balance at Dec. 31, 2021	295,526	$ 685,903	(396,271)	1,943	291,575	3,951
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(32,789)
Other comprehensive income	(1,722)
Ending balance (in shares) at Jun. 30, 2022		157,569,420
Ending balance at Jun. 30, 2022	270,516	$ 695,404	(429,054)	221	266,571	3,945
Beginning balance ( in shares) at Mar. 31, 2022		157,180,248
Beginning balance at Mar. 31, 2022	287,083	$ 690,424	(411,000)	3,709	283,133	3,950
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(18,059)		(18,054)		(18,054)	(5)
Other comprehensive income	(3,488)			(3,488)	(3,488)
Shares Issued For Cash By At The Market Offering Shares		356,028
Shares Issued For Cash By At The Market Offering	3,808	$ 3,808			3,808
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	86	86			86
Share-based compensation	1,147	$ 1,147			1,147
shares issued for exrcise of stock options (in shares)		24,326
Shares issued for the vesting of restricted stock units	67	$ 67			67
Cash paid to fund employee income tax withholding due upon vesting of restricted stock units	(11)	$ (11)			(11)
Shares issued for consulting services (in shares)		(5,183)
Shares issued for consulting services	$ (55)	$ (55)			(55)
Shares issued for exercise of stock appreciation rights (in shares)	3,635
Ending balance (in shares) at Jun. 30, 2022		157,569,420
Ending balance at Jun. 30, 2022	$ 270,516	$ 695,404	$ (429,054)	$ 221	$ 266,571	$ 3,945

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Statement of Cash Flows [Abstract]
Net loss for the period	$ (18,059)	$ (14,730)	$ (10,791)	$ (10,910)	$ (32,789)	$ (21,701)
Items not involving cash:
Depletion, depreciation and amortization	870		790		1,679	1,559
Share-based compensation					2,009	1,190
Change in value of warrant liabilities					0	7,050
Accretion of asset retirement obligation	510		351		904	672	$ 1,284
Unrealized foreign exchange gain					1,340	1,597
Revision and settlement of asset retirement obligation					(445)	(39)
Unrealized gain on available-for-sale assets					16,837	(1,021)
Other non-cash expenses (income)					259	(557)
Changes in assets and liabilities
Decrease (increase) in inventories					1,784	(1,635)
Increase in trade and other receivables					(675)	(47)
Increase in prepaid expenses and other assets					(6,594)	(182)
Decrease in accounts payable and accrued liabilities					(2,987)	(190)
Net cash (used in) provided by operating activities					(21,358)	(16,498)
INVESTING ACTIVITIES
Purchase of property, plant and equipment					705	757
Payments to Acquire Marketable Securities					(11,435)	0
Maturities and sales of marketable securities					0	2,554
Net cash (used in) provided by investing activities					(12,140)	1,797
FINANCING ACTIVITIES
Issuance of common shares for cash, net of issuance cost					7,886	67,099
Cash paid to fund employee income tax withholding due upon vesting of restricted stock units					(884)	(659)
Cash received from exercise of stock options					395	1,463
Cash received from exercise of warrants					0	4,079
Cash paid to settle and fund employee income tax withholding due upon exercise of stock appreciation rights					(11)	(48)
Cash received from non-controlling interest					0	229
Net cash (used in) provided by financing activities					7,386	72,163
Effect of exchange rate fluctuations on cash held in foreign currencies					(21)	1,409
Net change in cash, cash equivalents and restricted cash					(26,133)	58,871
Cash, cash equivalents and restricted cash, beginning of period		$ 132,822		$ 40,985	132,822	40,985	40,985
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	$ 106,689		$ 99,856		106,689	99,856	$ 132,822
Supplemental disclosure of cash flow information:
Interest					$ 17	$ 30

THE COMPANY AND DESCRIPTION OF

THE COMPANY AND DESCRIPTION OF BUSINESS	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
The Company and Description of Business	THE COMPANY AND DESCRIPTION OF BUSINESS Energy Fuels Inc. was incorporated under the laws of the Province of Alberta and was continued under the Business Corporations Act (Ontario). Energy Fuels Inc. and its subsidiary companies (collectively “ the Company ” or “ Energy Fuels ”) are engaged in uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties. As a part of these activities the Company also acquires, explores, evaluates and, if warranted, permits uranium properties. The Company’s final uranium product, uranium oxide concentrate (“ U 3 O 8 ” or “ uranium concentrate ”), known more commonly as “yellowcake,” is sold to customers for further processing into fuel for nuclear reactors. The Company also produces vanadium pentoxide (“ V 2 O 5 ”) along with uranium at its White Mesa Mill (the “ White Mesa Mill ” or the “ Mill ”), from certain of its Colorado Plateau properties as market conditions warrant and at times from solutions in its Mill tailings impoundment system. The Mill is also currently ramping up to commercial production of rare earth element (“ REE ”) carbonate (“ RE Carbonate ”) from various uranium- and REE-bearing materials acquired from third-parties, and is additionally evaluating the potential to recover radioisotopes from its existing process streams for use in targeted alpha therapy (“ TAT ”) therapeutics for the treatment of cancer. With its uranium, vanadium, REE and potential radioisotope production, the Mill is quickly becoming a critical minerals hub for the United States. Uranium is the fuel for carbon-free, emission-free baseload nuclear power – one of the cleanest forms of energy in the world. The REEs we are now producing are used for the manufacture of permanent magnets for electric vehicles, wind turbines and other clean energy and modern technologies. The very heart of our business – uranium and REE production and recycling – helps us play a big part in addressing global climate change and reducing air pollution, and the radioisotopes we are evaluating for recovery from our REE and uranium processing streams have the potential to provide the isotopes needed for emerging TAT cancer-fighting therapeutics. The Company is a “development stage issuer” as defined by S-K 1300, as it is engaged in the preparation of Mineral Reserves for extraction on at least one material property.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	BASIS OF PRESENTATION The consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principals (“ U.S. GAAP ”) and are presented in thousands of U.S. dollars, except for share and per share amounts. Certain footnote disclosures, where indicated, have share prices that are presented in Canadian dollars (“ Cdn$ ”). The condensed consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the United States Securities and Exchange Commission (“ SEC ”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included are adequate to make the information presented not misleading. In management’s opinion, these unaudited condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring items, which are necessary for the fair presentation of the Company’s financial position, results of operations and cash flows on a basis consistent with that of the Company’s audited consolidated financial statements for the year ended December 31, 2021. However, the results of operations for the interim periods may not be indicative of results to be expected for the full fiscal year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto and the summary of significant accounting policies included in the Company’s annual report on Form 10-K for the year ended December 31, 2021. The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All inter-company accounts and transactions have been eliminated. Recently Issued Accounting Pronouncements Not Yet Adopted Financial Instruments – Credit Losses In March 2022, the FASB issued ASU 2022-02, “Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructuring and Vintage Disclosures. This ASU clarifies the recognition and measurement guidance for troubled debt restructurings for creditors under ASC 310-40 and requires enhanced disclosure about modifications of borrowings made to borrowers experiencing financial difficulty. It also required the disclosure of current period write-offs by year of origination for financing receivables and net investments in leases within the scope of ASU 326-20. The Company is currently evaluating the impact of this statement and plans to adopt this prospectively on its effective date of January 1, 2023. Fair Value Measurement In June 2022, the FASB issued ASU 2022-03, “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sales Restrictions.” ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security should not be considered in measuring its fair value. The Company is currently evaluating the impact of this standard and expects to adopt this prospectively on its effective date of January 1, 2024.

MARKETABLE SECURITIES

MARKETABLE SECURITIES	6 Months Ended
	Jun. 30, 2022
Cash and Cash Equivalents [Abstract]
Marketable Securities	MARKETABLE SECURITIES For marketable debt securities, we have elected the fair value option for which changes in fair value are recorded in Other loss in the Condensed Consolidated Statement of Operations and Comprehensive Loss. The fair value option was elected for these securities as after consideration of our risks versus reward objectives, as well as our liquidity requirements, we may sell these debt securities prior to their stated maturities. The stated contractual maturity dates of marketable debt securities held as of June 30, 2022 are due between one and two years. No marketable debt securities were held as of December 31, 2021. The following table summarizes our marketable securities by significant investment categories as of June 30, 2022: Cost Basis Gross Unrealized Losses Gross Unrealized Gains Fair Value Marketable debt securities (1) $ 11,435 $ — $ 5 $ 11,440 Marketable equity securities 756 (401) — 355 Total marketable securities $ 12,191 $ (401) $ 5 $ 11,795 (1) Marketable debt securities are comprised primarily of notes of U.S. government agency bonds. The following table summarizes our marketable securities by significant investment categories as of December 31, 2021: Cost Basis Gross Unrealized Losses Gross Unrealized Gains Fair Value Marketable equity securities $ 756 $ (262) $ — $ 494

INVENTORIES

INVENTORIES	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Inventories	INVENTORIES June 30, 2022 December 31, 2021 Concentrates and work-in-progress $ 25,746 $ 27,619 Ore stockpiles 241 351 Raw materials and consumables 4,369 4,170 $ 30,356 $ 32,140 Inventories Current $ 28,565 $ 30,772 Long term - raw materials and consumables 1,791 1,368 $ 30,356 $ 32,140

PLANT AND EQUIPMENT AND MINERAL

PLANT AND EQUIPMENT AND MINERAL PROPERTIES	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Plant and Equipment and Mineral Properties	PROPERTY, PLANT AND EQUIPMENT AND MINERAL PROPERTIES The following is a summary of property, plant and equipment: June 30, 2022 December 31, 2021 Cost Accumulated Net Book Value Cost Accumulated Net Book Property, plant and equipment Nichols Ranch $ 29,210 $ (19,203) $ 10,007 $ 29,210 $ (18,185) $ 11,025 Alta Mesa 13,626 (5,451) 8,175 13,626 (4,996) 8,630 Equipment and other 16,290 (12,957) 3,333 15,079 (12,751) 2,328 Property, plant and equipment total $ 59,126 $ (37,611) $ 21,515 $ 57,915 $ (35,932) $ 21,983 Depreciation expense totaled $0.87 million and $1.68 million, respectively, for the three and six months ended June 30, 2022, compared to $0.79 million and $1.56 million, respectively, for the three and six months ended June 30, 2021. The following is a summary of mineral properties: June 30, 2022 December 31, 2021 Mineral properties Uranerz ISR properties $ 25,974 $ 25,974 Sheep Mountain 34,183 34,183 Roca Honda 22,095 22,095 Other 1,287 1,287 Mineral properties total $ 83,539 $ 83,539 On May 19, 2022, the Company announced that it had entered into two purchase agreements to acquire a total of seventeen mineral concessions in the State of Bahia, Brazil totaling approximately 37,300 acres or 58.3 square miles (the “Bahia Project”). Under the terms of the purchase agreements, the Company will enter into mineral rights transfer agreements with the sellers to acquire the seventeen mineral sand concessions. The transactions are expected to close in August of 2022. The total purchase price under the purchase agreements is $27.50 million consisting of deposit payments of $5.50 million due upon reaching certain milestones stated within the purchase agreements, and $22.00 million due at closing with the transfer and assignment of the mineral rights. As of June 30, 2022, the Company has made deposit payments totaling $5.50 million that will be attributable to the final purchase price under the purchase agreements, pending the close of the transactions. Additionally, direct deal costs of $0.50 million have been incurred related to such asset acquisitions. The purchase deposit payments and direct deal costs have been capitalized as Prepaid expenses and other assets in the Condensed Consolidated Balance Sheet.

ASSET RETIREMENT OBLIGATIONS AN

ASSET RETIREMENT OBLIGATIONS AND RESTRICTED CASH	6 Months Ended
	Jun. 30, 2022
Asset Retirement Obligation Disclosure [Abstract]
Asset Retirement Obligations and Restricted Cash	ASSET RETIREMENT OBLIGATIONS AND RESTRICTED CASHThe following table summarizes the Company’s asset retirement obligations: June 30, 2022 December 31, 2021 Asset retirement obligation, beginning of period $ 13,687 $ 13,038 Revision of estimate (445) (235) Disposal of non-core obligations — (269) Accretion of liabilities 904 1,284 Settlements — (131) Asset retirement obligation, end of period $ 14,146 $ 13,687 Asset retirement obligation: Current $ 219 $ 27 Non-current 13,927 13,660 Asset retirement obligation, end of period $ 14,146 $ 13,687 The asset retirement obligations of the Company are subject to legal and regulatory requirements. Estimates of the costs of reclamation are reviewed periodically by the Company and the applicable regulatory authorities. The above provision represents the Company’s best estimate of the present value of future reclamation costs, discounted using credit adjusted risk-free interest rates ranging from 9.50% to 11.67% and inflation rates ranging from 2.00% to 2.41%. The total undiscounted decommissioning liability at June 30, 2022 is $42.91 million (December 31, 2021 - $41.34 million). The Company has cash, cash equivalents and fixed income securities as collateral for various bonds posted in favor of the applicable state regulatory agencies in Arizona, Colorado, New Mexico, Texas, Utah and Wyoming, and the U.S. Bureau of Land Management (“ BLM ”) and U.S. Forest Service (“ USFS ”) for estimated reclamation costs associated with the Mill, Nichols Ranch, Alta Mesa and other mining properties. The restricted cash will be released when the Company has reclaimed a mineral property or restructured the surety and collateral arrangements. See Note 13 for a discussion of the Company’s surety bond commitments The following table summarizes the Company’s restricted cash: June 30, 2022 December 31, 2021 Restricted cash, beginning of period $ 20,305 $ 20,817 Additional collateral posted 21 48 Refunds of collateral — (560) Restricted cash, end of period $ 20,326 $ 20,305

LEASES

LEASES	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
LEASES	LEASES The Company’s leases are primarily for office space, the largest being an office building lease for the Company’s Lakewood, Colorado corporate offices. As of June 30, 2022, this lease has a remaining term of approximately 11 months and includes an option to extend the lease for one five-year term. Certain of our other leases include variable payments for lessor operating expenses that are not included within right-of-use (“ ROU ”) assets and lease liabilities in the Condensed Consolidated Balance Sheets. The Company’s lease agreements do not contain any material residual value guarantees or restrictive covenants. The Company’s operating lease expense is recognized on a straight-line basis over the lease term and is recorded in General and Administration expenses. Short-term leases, which have an initial term of 12 months or less, are not recorded in the Condensed Consolidated Balance Sheets. Total lease cost includes the following components: Three months ended Six months ended 2022 2021 2022 2021 Operating leases $ 77 $ 77 $ 154 $ 154 Short-term leases 79 81 159 162 Total lease expense $ 156 $ 158 $ 313 $ 316 The weighted average remaining lease term and weighted average discount rate were as follows: Six months ended 2022 2021 Weighted average remaining lease term of operating leases 0.9 years 1.9 years Weighted average discount rate of operating leases 9.0 % 9.0 % Supplemental cash flow information related to leases was as follows: Three months ended Six months ended 2022 2021 2022 2021 Operating cash flow information: Cash paid for amounts included in the measurement of operating lease liabilities $ 87 $ 85 $ 174 $ 170

CAPITAL STOCK

CAPITAL STOCK	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Capital Stock	CAPITAL STOCK Authorized capital stock The Company is authorized to issue an unlimited number of Common Shares without par value, unlimited Preferred Shares issuable in series, and unlimited Series A Preferred Shares. The Series A Preferred Shares issuable are non-redeemable, non-callable, non-voting and have no right to dividends. The Preferred Shares issuable in series will have the rights, privileges, restrictions and conditions assigned to the particular series upon the Board of Directors approving their issuance. Issued capital stock In the six months ended June 30, 2022, the Company issued 0.77 million Common Shares under the Company’s ATM for net proceeds of $7.89 million after share issuance costs.

BASIC AND DILUTED LOSS PER COMM

BASIC AND DILUTED LOSS PER COMMON SHARE	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Basic and Diluted Loss Per Common Share	BASIC AND DILUTED LOSS PER COMMON SHARE The calculation of basic and diluted loss per share after adjustment for the effects of all potential dilutive Common Shares, is as follows: Three months ended Six months ended 2022 2021 2022 2021 Net loss attributable to owners of the Company $ (18,054) $ (10,784) $ (32,783) $ (21,692) Basic and diluted weighted average common shares outstanding 157,491,807 144,450,494 157,044,331 140,923,146 Net loss per common share $ (0.11) $ (0.07) $ (0.21) $ (0.15) For the six months ended June 30, 2022, 4.03 million stock options, restricted stock units, stock appreciation rights, and warrants have been excluded from the calculation of diluted net loss per common share as their effect would have been anti-dilutive (June 30, 2021 - 6.29 million).

SHARE-BASED PAYMENTS

SHARE-BASED PAYMENTS	6 Months Ended
	Jun. 30, 2022
Share-based Payment Arrangement [Abstract]
Share-Based Payments	SHARE-BASED PAYMENTS The Company maintains an equity incentive plan, known as the 2021 Amended and Restated Omnibus Equity Incentive Compensation Plan (the “ Compensation Plan ”), for directors, executives, eligible employees and consultants. Existing equity incentive awards include employee non-qualified stock options, restricted stock units (“ RSUs ”) and stock appreciation rights (“ SARs ”). The Company issues new Common Shares to satisfy exercises and vesting under its equity incentive awards. At June 30, 2022, a total of 15,756,942 Common Shares were authorized for future equity incentive plan awards. On January 25, 2022, the Company’s Board of Directors approved the issuance of 0.10 million stock options, 0.33 million RSUs, and 0.83 million SARs on the terms and conditions discussed below. Due to an administrative delay in communicating the terms of certain awards to some grantees, the Company determined that, for accounting purposes only, the grant date for such awards was not the date of the Board approval but, instead, April 18, 2022, being the date that the key award terms were communicated to those certain grantees. As such, 0.07 million stock options, 0.02 million RSUs, and 0.10 SARs are treated, for accounting purposes, as having a grant date of April 18, 2022. However, this accounting change did not alter the fundamental terms of the grants, as approved by the Board, and all such grants retained their original term (commencing as of January 25, 2022), vesting schedules, vesting performance metrics and exercise price, as each is applicable. Employee Stock Options The Company, under the Compensation Plan, may grant stock options to directors, executives, employees and consultants to purchase Common Shares of the Company. The exercise price of the stock options is set as the higher of the Company’s closing share price on the NYSE American on the day before the grant date and the five-day volume weighted average price (“ VWAP ”) on the NYSE American ending on the day before the grant date. Stock options granted under the Compensation Plan generally vest over a period of two years or more, and are generally exercisable over a period of five years from the grant date, such period not to exceed 10 years. During the six months ended June 30, 2022, the Company granted 0.11 million stock options under the Compensation Plan (June 30, 2021 - 0.16 million). The fair value of the stock options granted under the Compensation Plan for the six months ended June 30, 2022 was estimated at the date of grant, using the Black-Scholes Option Valuation Model, with the following weighted average assumptions: Risk-free interest rate 2.34 % Expected life (in years) 3.18 Expected volatility (1) 73.01 % Expected dividend yield — % Weighted average grant date fair value $ 5.05 (1) Expected volatility is measured based on the Company’s historical share price volatility over a period equivalent to the expected life of the stock options. The summary of the Company’s stock options at June 30, 2022 and December 31, 2021, respectively, and the changes for the fiscal periods ending on those dates, are presented below: Range of Exercise Prices Number of Shares Weighted Average Weighted Average Remaining Contractual Life (Years) Intrinsic Value Outstanding, December 31, 2020 $1.70 - $15.61 1,609,087 $ 2.91 Granted 3.89 - 8.41 169,310 3.99 Exercised 1.70 - 7.42 (775,814) 2.95 Forfeited 1.76 - 5.91 (8,048) 3.16 Expired 1.70 - 15.61 (51,653) 8.14 Outstanding, December 31, 2021 $1.70 - $8.41 942,882 $ 2.79 Granted 5.84 - 10.03 109,328 6.50 Exercised 1.70 - 5.18 (160,252) 2.45 Forfeited 3.89 - 6.47 (3,385) 5.78 Expired 2.35 (15,506) 2.35 Outstanding, June 30, 2022 $1.70 - $10.03 873,067 $ 3.31 2.34 $ 1,584 Exercisable, June 30, 2022 $1.70 - $7.14 721,496 $ 2.79 1.92 $ 1,544 The total intrinsic value of options exercised in the six months ended June 30, 2022 was $1.16 million (June 30, 2021 – $1.75 million). The summary of the Company’s non-vested stock options at June 30, 2022 and December 31, 2021, respectively, and the changes for the fiscal periods ending on those dates, are presented below: Number of Shares Weighted Average Grant Date Fair Value Non-vested, December 31, 2020 403,990 $ 0.94 Granted 169,310 2.06 Vested (351,934) 1.23 Forfeited (8,049) 1.60 Non-vested, December 31, 2021 213,317 $ 1.34 Granted 109,328 5.05 Vested (167,689) 1.12 Forfeited (3,385) 5.00 Non-vested, June 30, 2022 151,571 $ 4.17 Restricted Stock Units The Company grants RSUs to directors, executives and eligible employees. Awards for executives and eligible employees are determined as a target percentage of base salary and generally vest over three years. Holders of unvested RSUs do not have voting rights on those RSUs. The RSUs are subject to forfeiture risk and other restrictions. Upon vesting, the employee is entitled to receive one Common Share of the Company for each RSU at no additional payment. During the six months ended June 30, 2022, the Company’s Board of Directors issued 0.35 million RSUs under the Compensation Plan (June 30, 2021 - 0.44 million). The fair value of RSUs granted was determined at the date of grant based on the Company’s share price on the NYSE American. The summary of the Company’s non-vested RSUs at June 30, 2022 and December 31, 2021, respectively, and the changes for the fiscal periods ending on those dates, are presented below: Number of Shares Weighted Average Grant Date Fair Value Non-vested, December 31, 2020 1,094,056 $ 1.98 Granted 441,241 3.89 Vested (635,233) 1.94 Non-vested, December 31, 2021 900,064 $ 2.94 Granted 354,406 6.59 Vested (518,856) 2.93 Forfeited (42,082) 5.34 Non-vested, June 30, 2022 693,532 $ 4.66 The total intrinsic value and fair value of RSUs that vested and were settled for equity in the six months ended June 30, 2022 was $2.93 million (June 30, 2021 – $2.67 million). Stock Appreciation Rights The Company may grant SARs to directors, executives, and eligible employees. During the year ended December 31, 2019, the Company’s Board of Directors issued 2.20 million SARs under the Compensation Plan with a fair value of $1.25 per SAR. These SARs are intended to provide additional long-term performance-based equity incentives for the Company’s senior management. The SARs are performance-based because they only vest upon the achievement of performance goals designed to significantly increase shareholder value. Each SAR granted entitles the holder to receive, upon a valid exercise, payment from the Company in cash or Common Shares (at the sole discretion of the Company) in an amount representing the difference between the fair market value (“ FMV ”) of the Company’s Common Shares on the date of exercise and $2.92 (the closing market price or “ Grant Price ” at the time of grant). Fair Market Value as used herein means the closing price of the Shares on the TSX or the NYSE American on the trading day immediately prior to the date of exercise. The term of the SARs grant is five years, with SARs vesting only upon the achievement of the following performance goals: as to one-third of the SARs granted, automatically upon the 90-calendar-day VWAP of the Company’s Common Shares on the NYSE American equaling or exceeding $5.00 for any continuous 90-calendar-day period; as to an additional one-third of the SARs granted, automatically upon the 90-calendar-day VWAP of the Company’s Common Shares on the NYSE American equaling or exceeding $7.00 for any continuous 90-calendar-day period; and as to the final one-third of the SARs granted, automatically upon the 90-calendar-day VWAP of the Company’s Common Shares on the NYSE American equaling or exceeding $10.00 for any continuous 90-calendar-day period. Further, notwithstanding the foregoing vesting schedule, no SARs were able to be exercised by the holder for an initial period of one year from the Date of Grant; the date first exercisable being January 22, 2020. The first two tranches of these vesting performance goals were met prior to the six months ended June 30, 2022. During the six months ended June 30, 2022, the Company’s Board of Directors issued 0.83 million SARs under the Compensation Plan (June 30, 2021 – nil). The fair value of the SARs granted during the six months ended June 30, 2022 was estimated at the date of grant using a Monte Carlo simulation, with the following weighted average assumptions: Risk-free interest rate 1.68 % Expected life (in years) (1) 4.98 Expected volatility (2) 72.81 % Expected dividend yield — % Weighted average grant date fair value $ 3.99 (1) Monte Carlo analysis of SARs assumes employee suboptimal exercise at first vesting time for each tranche. (2) Expected volatility is measured based on the Company’s historical share price volatility over a period equivalent to the expected life of the SARs. Each SAR granted entitles the holder to receive, upon a valid exercise, payment from the Company in cash or Common Shares (at the sole discretion of the Company) in an amount representing the difference between the FMV of the Company’s Common Shares on the date of exercise and $6.47 (the Grant Price at the time of grant). The term of the SARs grant is five years, with SARs vesting only upon the achievement of the following performance goals: as to one-third of the SARs granted, automatically upon the 90-calendar-day VWAP of the Company’s Common Shares on the NYSE American equaling or exceeding $12.00 for any continuous 90-calendar-day period; as to an additional one-third of the SARs granted, automatically upon the 90-calendar-day VWAP of the Company’s Common Shares on the NYSE American equaling or exceeding $14.00 for any continuous 90-calendar-day period; and as to the final one-third of the SARs granted, automatically upon the 90-calendar-day VWAP of the Company’s Common Shares on the NYSE American equaling or exceeding $16.00 for any continuous 90-calendar-day period. Further, notwithstanding the foregoing vesting schedule, no SARs may be exercised by the holder for an initial period of one year from the date of grant; the date first exercisable being January 25, 2023. As a result, the SARs granted in the first quarter of 2022 for 2021 performance are a long-term equity incentive and are 100% performance based. The summary of the Company’s SARs at June 30, 2022 and December 31, 2021, respectively, and the changes for the fiscal periods ending on those dates, are presented below: Number of Shares Weighted Average Weighted Average Remaining Contractual Life (Years) Intrinsic Value Outstanding, December 31, 2020 1,720,623 $ 2.92 Exercised (48,201) 2.92 Outstanding, December 31, 2021 1,672,422 $ 2.92 Granted 833,315 6.47 Exercised (6,730) 2.92 Forfeited (34,921) 5.79 Outstanding, June 30, 2022 2,464,086 $ 4.08 2.55 $ 3,301 Exercisable, June 30, 2022 1,092,143 $ 2.92 1.56 $ 2,173 The summary of the Company’s non-vested SARs at June 30, 2022 and December 31, 2021, respectively, and the changes for the fiscal periods ending on those dates, are presented below: Number of Shares Weighted Average Grant Date Fair Value Non-vested, December 31, 2020 1,720,623 $ 1.25 Vested (1,147,074) 1.27 Non-vested, December 31, 2021 573,549 $ 1.19 Granted 833,315 3.99 Forfeited (34,921) 4.05 Non-vested, June 30, 2022 1,371,943 $ 2.83 The components of share-based compensation are as follows: Three months ended Six months ended 2022 2021 2022 2021 Recognized expense Stock options $ 109 $ 37 $ 141 $ 240 RSU awards (1) 488 390 972 753 SARs 550 62 896 197 Total recognized expense $ 1,147 $ 489 $ 2,009 $ 1,190 (1) The fair value of the RSUs granted under the Compensation Plan for the six months ended June 30, 2022 and 2021 was estimated at the date of grant, using the stated market price on the NYSE American. At June 30, 2022, there were $0.46 million, $1.82 million, and $2.30 million of unrecognized compensation costs related to the unvested stock options, RSU awards and SARs, respectively, to be recognized over a weighted average period of 1.54 years, 1.96 years, and 1.22 years, respectively.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXESAs of June 30, 2022, the Company does not believe that it is more likely than not that it will fully realize the benefit of the deferred tax assets. As such, the Company recognized a full valuation allowance against the net deferred tax assets as of June 30, 2022 and December 31, 2021.

SUPPLEMENTAL FINANCIAL INFORMAT

SUPPLEMENTAL FINANCIAL INFORMATION	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Financial Information	SUPPLEMENTAL FINANCIAL INFORMATION The components of other income (loss) are as follows: Three months ended Six months ended 2022 2021 2022 2021 Interest income $ 12 $ 14 $ 24 $ 25 Change in value of investments accounted for at fair value (13,419) (435) (16,837) 1,021 Change in value of warrant liabilities — (3,546) — (7,050) Foreign exchange gain 2,345 659 1,132 320 Other (282) 873 (171) 1,202 Other loss $ (11,344) $ (2,435) $ (15,852) $ (4,482) The components of trade and other receivables are as follows: June 30, 2022 December 31, 2021 Trade receivables $ 2,534 $ 1,858 Other 142 1,753 Notes receivable, net 343 343 $ 3,019 $ 3,954 As of June 30, 2022, the Company has $1.75 million in current and long-term other receivables with $1.65 million due from Consolidated Uranium Inc. (“ CUR ”, f/k/a International Consolidated Uranium, Inc., TSX-V:CUR) pursuant to the terms of the asset purchase agreement related to the sale of certain non-core conventional uranium projects and resulting deferred cash payments, and pursuant to the terms of the ongoing operating agreement with CUR. The components of accounts payable and accrued liabilities are as follows: June 30, 2022 December 31, 2021 Accounts payable $ 2,159 $ 3,038 Payroll liabilities 465 1,988 Other accrued liabilities 660 738 $ 3,284 $ 5,764

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES General legal matters Other than routine litigation incidental to our business, or as described below, the Company is not currently a party to any material pending legal proceedings that management believes would be likely to have a material adverse effect on our financial position, results of operations or cash flows. White Mesa Mill In 2013, the Ute Mountain Ute Tribe filed a Petition to Intervene and Request for Agency Action challenging the Corrective Action Plan approved by the State of Utah Department of Environmental Quality (“ UDEQ ”) relating to nitrate contamination in the shallow aquifer at the Mill. The challenge is currently being evaluated and may involve the appointment of an administrative law judge (“ ALJ ”) to hear the matter. The Company does not consider this action to have any merit. If the petition is successful, the likely outcome would be a requirement to modify or replace the existing Corrective Action Plan. At this time, the Company does not believe any such modification or replacement would materially affect its financial position, results of operations or cash flows. However, the scope and costs of remediation under a revised or replaced Corrective Action Plan have not yet been determined and could be significant. The UDEQ renewed in January 2018, then reissued with minor corrections in February 2018, the Mill’s radioactive materials license (the “ Mill License ”) for another ten years and the Groundwater Discharge Permit (the “ GWDP ”) for another five years, after which further applications for renewal of the Mill License and GWDP will need to be submitted. During the review period for each application for renewal, the Mill can continue to operate under its existing Mill License and GWDP until such time as the renewed Mill License or GWDP is issued. In 2018, the Grand Canyon Trust, Ute Mountain Ute Tribe and Uranium Watch (collectively, the “ Mill Plaintiffs ”) served Petitions for Review challenging UDEQ’s renewal of the Mill License and GWDP and Requests for Appointment of an ALJ, which they later agreed to suspend pursuant to a Stipulation and Agreement with UDEQ, effective June 4, 2018. The Company and the Mill Plaintiffs held multiple discussions over the course of 2018 and 2019 in an effort to settle the dispute outside of any judicial proceeding. In February 2019, the Mill Plaintiffs submitted to the Company their proposal for reaching a settlement agreement. The proposal remains under consideration by the Company. The Company does not consider these challenges to have any merit and, if a settlement cannot be reached, the Company intends to participate with UDEQ in defending against the challenges. If the challenges are successful, the likely outcome would be a requirement to modify the renewed Mill License and/or GWDP. At this time, the Company does not believe that any such modification would materially affect its financial position, results of operations or cash flows. On August 26, 2021, the Ute Mountain Ute Tribe filed a Petition to Intervene and Petition for Review challenging the UDEQ’s approval of Amendment No. 10 to the Mill License, which expanded the list of Alternate Feed Materials that the Mill is authorized to accept and process for its source material content. Then, on November 18, 2021, the Tribe filed its Request for Appointment of an ALJ, followed shortly thereafter by a stay on the request in accordance with a Stipulation and Agreement between the Tribe, UDEQ and the Company. The Company does not consider this action to have any merit. If the stay is lifted, an ALJ is appointed and the petition is successful, the likely outcome would be a requirement to modify or revoke the Mill License amendment. At this time, the Company does not believe any such modification or revocation would materially affect its financial position, results of operations or cash flows. Pinyon Plain Project In March 2013, the Center for Biological Diversity, the Grand Canyon Trust, the Sierra Club and the Havasupai Tribe (the “ Pinyon Plaintiffs ”) filed a complaint in the U.S. District Court for the District of Arizona (the “ District Court ”) against the USFS and the USFS Forest Supervisor for the Kaibab National Forest (together, the “ Defendants ”) seeking an order (a) declaring that the USFS failed to comply with environmental, mining, public land, and historic preservation laws in relation to our Pinyon Plain Project (formerly known as the Canyon Project), (b) setting aside any approvals regarding exploration and mining operations at the Pinyon Plain Project, and (c) directing operations to cease at the Pinyon Plain Project and enjoining the USFS from allowing any further exploration or mining-related activities at the Pinyon Plain Project until the USFS fully complies with all applicable laws. In April 2013, the Pinyon Plaintiffs filed a Motion for Preliminary Injunction, which was later denied by the District Court. In April 2015, the District Court issued its final ruling on the merits in favor of the Defendants and the Company and against the Pinyon Plaintiffs on all counts. The Pinyon Plaintiffs appealed the District Court’s ruling on the merits to the United States Ninth Circuit Court of Appeals (the “ Ninth Circuit ”) and filed motions for an injunction pending appeal with the District Court. Those motions for an injunction pending appeal were denied by the District Court on May 26, 2015. Thereafter, the Pinyon Plaintiffs filed urgent motions for an injunction pending appeal with the Ninth Circuit, which were denied on June 30, 2015. The hearing on the merits was held at the Ninth Circuit on December 15, 2016, which resulted in a favorable ruling for the Defendants a year later. The Pinyon Plaintiffs petitioned the Ninth Circuit for a rehearing en banc and, on October 25, 2018, the Ninth Circuit panel withdrew its prior opinion and filed a new opinion, which affirmed the prior opinion with one exception to the District Court’s decision. The Ninth Circuit panel reversed itself on its prudential standing analysis as applied to the fourth claim on “valid existing rights,” having initially determined that the Pinyon Plaintiffs lacked standing under the General Mining Law of 1872 (the “ Mining Law ”). The panel remanded the claim back to the District Court to hear on the merits, with the Pinyon Plaintiffs alleging that the USFS did not consider all relevant costs in analyzing whether the Company satisfied the Mining Law’s “prudent person test” in its mineral examination and, thus, erred in concluding that the Company has valid existing rights to operate the Pinyon Plain Mine on lands otherwise subject to a 2012 U.S. Department of Interior withdrawal from location and entry. On May 22, 2020, after the matters were briefed, the District Court issued its final order in favor of the Defendants, which the Pinyon Plaintiffs thereafter appealed to the Ninth Circuit. In December 2020, the Pinyon Plaintiffs filed their Appellant’s Opening Brief with the Ninth Circuit and, in April 2021, the Defendants filed their respective Answering Briefs. Oral arguments were held remotely on August 30, 2021. On February 22, 2022, the Ninth Circuit filed its Opinion in favor of the USFS and the Company. The Pinyon Plaintiffs did not request a hearing on this matter in front of the U.S. Supreme Court. As such, this matter is now resolved. Surety Bonds The Company has indemnified third-party companies to provide surety bonds as collateral for the Company’s asset retirement obligations. The Company is obligated to replace this collateral in the event of a default and is obligated to repay any reclamation or closure costs due. As of June 30, 2022, the Company has $20.33 million posted as collateral against an undiscounted asset retirement obligation of $42.91 million (December 31, 2021 - $20.31 million posted as collateral against an undiscounted asset retirement obligation of $41.34 million). Commitments The Company is contractually obligated under a Sales and Agency Agreement appointing an exclusive sales and marketing agent for all vanadium pentoxide produced by the Company.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	Jun. 01, 2021
Related Party Transactions [Abstract]
Related Party Transactions	RELATED PARTY TRANSACTIONSOn May 17, 2017, the Board of Directors of the Company appointed Robert W. Kirkwood and Benjamin Eshleman III to the Board of Directors of the Company. Mr. Kirkwood is a principal of the Kirkwood Companies, including Kirkwood Oil and Gas LLC, Wesco Operating, Inc., and United Nuclear LLC (“ United Nuclear ”). United Nuclear owns a 19% interest in the Company’s Arkose Mining Venture while the Company owns the remaining 81%. The Company acts as manager of the Arkose Mining Venture and has management and control over operations carried out by the Arkose Mining Ve nture. The Arkose Mining Venture is a contractual joint venture governed by a venture agreement dated as of January 15, 2008 and entered into by Uranerz Energy Corporation, a wholly owned, indirectly held subsidiary of the Company (“ Uranerz ”) and United Nuclear (the “ Venture Agreement ”). United Nuclear contrib uted nil to the expenses of the Arkose Joint Venture based on the approved budget for the six months ended June 30, 2022 (June 30, 2021 - $0.23 million). On June 1, 2022, Uranerz renewed for a third year its Casper, Wyoming-based Office Lease Agreement with Metro, Inc. where Mr. Kirkwood acts as General Manager. Consistent with the prior year’s lease, the term is for a period of 12 months with rent in the amount of $15,000 paid in $1,250 monthly increments. The original Office Lease Agreement was entered into by the parties on June 1, 2020, for a period of 12 months, with rent in the amount of $12,000 paid in $1,000 monthly increments. Mr. Benjamin Eshleman III is President of Mesteña LLC, which became a shareholder of the Company through the Company’s acquisition of Mesteña Uranium, L.L.C (now Alta Mesa LLC) and certain of its affiliates (collectively, the “ Acquired Companies ”) in June 2016. Pursuant to the purchase agreement, the Alta Mesa Properties held by the Acquired Companies are subject to a royalty of 3.125% of the value of the recovered U 3 O 8 from the Alta Mesa Properties sold at a price of $65.00 per pound or less, 6.25% of the value of the recovered U 3 O 8 from the Alta Mesa Properties sold at a price greater than $65.00 per pound up to and including $95.00 per pound, and 7.5% of the value of the recovered U 3 O 8 from the Alta Mesa Properties sold at a price greater than $95.00 per pound. The royalties are held by Mr. Eshleman and his extended family. In addition, Mr. Eshleman and certain members of his extended family are parties to surface use agreements that entitle them to surface use payments from the Acquired Companies in certain circumstances. The Alta Mesa Properties are currently being maintained on care and maintenance to enable the Company to restart operations as market conditions warrant, and as such, no royalty payments were made during the six months ended June 30, 2022 or 2021. The Company makes surface use payments on an annual basis to Mr. Eshleman and his immediate family members and has accrued $0.22 million as of June 30, 2022 (December 31, 2021 - nil). On October 27, 2021, the Company began providing services to CUR under a mine operating agreement. Amounts earned during the six months ended June 30, 2022 and due to the Company from CUR at June 30, 2022 were approximately $0.40 million. The Company provided no services to CUR under the toll milling agreement during the six months ended June 30, 2022.

FAIR VALUE ACCOUNTING

FAIR VALUE ACCOUNTING	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Accounting	FAIR VALUE ACCOUNTING Assets and liabilities measured at fair value on a recurring basis The following tables set forth the fair value of the Company’s assets and liabilities measured at fair value on a recurring basis (at least annually) by level within the fair value hierarchy as of June 30, 2022. As required by accounting guidance, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. As of June 30, 2022, the fair values of cash and cash equivalents, restricted cash, short-term deposits, receivables, accounts payable and accrued liabilities approximate their carrying values because of the short-term nature of these instruments. Level 1 Level 2 Level 3 Total Investments at fair value $ 21,043 $ 259 $ — $ 21,302 Marketable equity securities 355 — — 355 Marketable debt securities — 11,440 — 11,440 $ 21,398 $ 11,699 $ — $ 33,097 The Company’s investments in marketable equity securities are exchange-traded and are valued using quoted market prices in active markets and, as such, are classified within Level 1 of the fair value hierarchy. The Company's investments in marketable debt securities are valued using quoted prices of a pricing service and as such are classified within Level 2 of the fair value hierarchy. The Company’s investments accounted for at fair value consisting of Common Shares are valued using quoted market prices in active markets and as such are classified within Level 1 of the fair value hierarchy. The Company’s investments accounted for at fair value consisting of warrants are valued using the Black-Scholes option model based on observable inputs and as such are classified within Level 2 of the hierarchy.

MARKETABLE SECURITIES (Tables)

MARKETABLE SECURITIES (Tables)	6 Months Ended
	Jun. 30, 2022
Cash and Cash Equivalents [Abstract]
Marketable Securities	The following table summarizes our marketable securities by significant investment categories as of June 30, 2022: Cost Basis Gross Unrealized Losses Gross Unrealized Gains Fair Value Marketable debt securities (1) $ 11,435 $ — $ 5 $ 11,440 Marketable equity securities 756 (401) — 355 Total marketable securities $ 12,191 $ (401) $ 5 $ 11,795 (1) Marketable debt securities are comprised primarily of notes of U.S. government agency bonds. The following table summarizes our marketable securities by significant investment categories as of December 31, 2021: Cost Basis Gross Unrealized Losses Gross Unrealized Gains Fair Value Marketable equity securities $ 756 $ (262) $ — $ 494

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	June 30, 2022 December 31, 2021 Concentrates and work-in-progress $ 25,746 $ 27,619 Ore stockpiles 241 351 Raw materials and consumables 4,369 4,170 $ 30,356 $ 32,140 Inventories Current $ 28,565 $ 30,772 Long term - raw materials and consumables 1,791 1,368 $ 30,356 $ 32,140

PLANT AND EQUIPMENT AND MINER_2

PLANT AND EQUIPMENT AND MINERAL PROPERTIES (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	The following is a summary of property, plant and equipment: June 30, 2022 December 31, 2021 Cost Accumulated Net Book Value Cost Accumulated Net Book Property, plant and equipment Nichols Ranch $ 29,210 $ (19,203) $ 10,007 $ 29,210 $ (18,185) $ 11,025 Alta Mesa 13,626 (5,451) 8,175 13,626 (4,996) 8,630 Equipment and other 16,290 (12,957) 3,333 15,079 (12,751) 2,328 Property, plant and equipment total $ 59,126 $ (37,611) $ 21,515 $ 57,915 $ (35,932) $ 21,983
Schedule of Summary of Mineral Properties	The following is a summary of mineral properties: June 30, 2022 December 31, 2021 Mineral properties Uranerz ISR properties $ 25,974 $ 25,974 Sheep Mountain 34,183 34,183 Roca Honda 22,095 22,095 Other 1,287 1,287 Mineral properties total $ 83,539 $ 83,539

ASSET RETIREMENT OBLIGATIONS _2

ASSET RETIREMENT OBLIGATIONS AND RESTRICTED CASH (Tables)	6 Months Ended
	Jun. 30, 2022
Asset Retirement Obligation Disclosure [Abstract]
Schedule of Change in Asset Retirement Obligation	The following table summarizes the Company’s asset retirement obligations: June 30, 2022 December 31, 2021 Asset retirement obligation, beginning of period $ 13,687 $ 13,038 Revision of estimate (445) (235) Disposal of non-core obligations — (269) Accretion of liabilities 904 1,284 Settlements — (131) Asset retirement obligation, end of period $ 14,146 $ 13,687 Asset retirement obligation: Current $ 219 $ 27 Non-current 13,927 13,660 Asset retirement obligation, end of period $ 14,146 $ 13,687
Schedule of Restricted Cash and Cash Equivalents	The following table summarizes the Company’s restricted cash: June 30, 2022 December 31, 2021 Restricted cash, beginning of period $ 20,305 $ 20,817 Additional collateral posted 21 48 Refunds of collateral — (560) Restricted cash, end of period $ 20,326 $ 20,305

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Lease, Cost	Total lease cost includes the following components: Three months ended Six months ended 2022 2021 2022 2021 Operating leases $ 77 $ 77 $ 154 $ 154 Short-term leases 79 81 159 162 Total lease expense $ 156 $ 158 $ 313 $ 316 Six months ended 2022 2021 Weighted average remaining lease term of operating leases 0.9 years 1.9 years Weighted average discount rate of operating leases 9.0 % 9.0 % Supplemental cash flow information related to leases was as follows: Three months ended Six months ended 2022 2021 2022 2021 Operating cash flow information: Cash paid for amounts included in the measurement of operating lease liabilities $ 87 $ 85 $ 174 $ 170

BASIC AND DILUTED LOSS PER CO_2

BASIC AND DILUTED LOSS PER COMMON SHARE (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The calculation of basic and diluted loss per share after adjustment for the effects of all potential dilutive Common Shares, is as follows: Three months ended Six months ended 2022 2021 2022 2021 Net loss attributable to owners of the Company $ (18,054) $ (10,784) $ (32,783) $ (21,692) Basic and diluted weighted average common shares outstanding 157,491,807 144,450,494 157,044,331 140,923,146 Net loss per common share $ (0.11) $ (0.07) $ (0.21) $ (0.15)

SHARE-BASED PAYMENTS (Tables)

SHARE-BASED PAYMENTS (Tables)	6 Months Ended
	Jun. 30, 2022
Share-based Payment Arrangement [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair value of the stock options granted under the Compensation Plan for the six months ended June 30, 2022 was estimated at the date of grant, using the Black-Scholes Option Valuation Model, with the following weighted average assumptions: Risk-free interest rate 2.34 % Expected life (in years) 3.18 Expected volatility (1) 73.01 % Expected dividend yield — % Weighted average grant date fair value $ 5.05 (1) Expected volatility is measured based on the Company’s historical share price volatility over a period equivalent to the expected life of the stock options.
Schedule of Share-based Compensation, Stock Options, Activity	The summary of the Company’s stock options at June 30, 2022 and December 31, 2021, respectively, and the changes for the fiscal periods ending on those dates, are presented below: Range of Exercise Prices Number of Shares Weighted Average Weighted Average Remaining Contractual Life (Years) Intrinsic Value Outstanding, December 31, 2020 $1.70 - $15.61 1,609,087 $ 2.91 Granted 3.89 - 8.41 169,310 3.99 Exercised 1.70 - 7.42 (775,814) 2.95 Forfeited 1.76 - 5.91 (8,048) 3.16 Expired 1.70 - 15.61 (51,653) 8.14 Outstanding, December 31, 2021 $1.70 - $8.41 942,882 $ 2.79 Granted 5.84 - 10.03 109,328 6.50 Exercised 1.70 - 5.18 (160,252) 2.45 Forfeited 3.89 - 6.47 (3,385) 5.78 Expired 2.35 (15,506) 2.35 Outstanding, June 30, 2022 $1.70 - $10.03 873,067 $ 3.31 2.34 $ 1,584 Exercisable, June 30, 2022 $1.70 - $7.14 721,496 $ 2.79 1.92 $ 1,544 Number of Shares Weighted Average Grant Date Fair Value Non-vested, December 31, 2020 403,990 $ 0.94 Granted 169,310 2.06 Vested (351,934) 1.23 Forfeited (8,049) 1.60 Non-vested, December 31, 2021 213,317 $ 1.34 Granted 109,328 5.05 Vested (167,689) 1.12 Forfeited (3,385) 5.00 Non-vested, June 30, 2022 151,571 $ 4.17
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The summary of the Company’s non-vested RSUs at June 30, 2022 and December 31, 2021, respectively, and the changes for the fiscal periods ending on those dates, are presented below: Number of Shares Weighted Average Grant Date Fair Value Non-vested, December 31, 2020 1,094,056 $ 1.98 Granted 441,241 3.89 Vested (635,233) 1.94 Non-vested, December 31, 2021 900,064 $ 2.94 Granted 354,406 6.59 Vested (518,856) 2.93 Forfeited (42,082) 5.34 Non-vested, June 30, 2022 693,532 $ 4.66 The summary of the Company’s SARs at June 30, 2022 and December 31, 2021, respectively, and the changes for the fiscal periods ending on those dates, are presented below: Number of Shares Weighted Average Weighted Average Remaining Contractual Life (Years) Intrinsic Value Outstanding, December 31, 2020 1,720,623 $ 2.92 Exercised (48,201) 2.92 Outstanding, December 31, 2021 1,672,422 $ 2.92 Granted 833,315 6.47 Exercised (6,730) 2.92 Forfeited (34,921) 5.79 Outstanding, June 30, 2022 2,464,086 $ 4.08 2.55 $ 3,301 Exercisable, June 30, 2022 1,092,143 $ 2.92 1.56 $ 2,173 The summary of the Company’s non-vested SARs at June 30, 2022 and December 31, 2021, respectively, and the changes for the fiscal periods ending on those dates, are presented below: Number of Shares Weighted Average Grant Date Fair Value Non-vested, December 31, 2020 1,720,623 $ 1.25 Vested (1,147,074) 1.27 Non-vested, December 31, 2021 573,549 $ 1.19 Granted 833,315 3.99 Forfeited (34,921) 4.05 Non-vested, June 30, 2022 1,371,943 $ 2.83
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award	The components of share-based compensation are as follows: Three months ended Six months ended 2022 2021 2022 2021 Recognized expense Stock options $ 109 $ 37 $ 141 $ 240 RSU awards (1) 488 390 972 753 SARs 550 62 896 197 Total recognized expense $ 1,147 $ 489 $ 2,009 $ 1,190 (1) The fair value of the RSUs granted under the Compensation Plan for the six months ended June 30, 2022 and 2021 was estimated at the date of grant, using the stated market price on the NYSE American.
Share-based Payment Arrangement, Restricted Stock Unit, Activity	The fair value of the SARs granted during the six months ended June 30, 2022 was estimated at the date of grant using a Monte Carlo simulation, with the following weighted average assumptions: Risk-free interest rate 1.68 % Expected life (in years) (1) 4.98 Expected volatility (2) 72.81 % Expected dividend yield — % Weighted average grant date fair value $ 3.99 (1) Monte Carlo analysis of SARs assumes employee suboptimal exercise at first vesting time for each tranche. (2) Expected volatility is measured based on the Company’s historical share price volatility over a period equivalent to the expected life of the SARs.

SUPPLEMENTAL FINANCIAL INFORM_2

SUPPLEMENTAL FINANCIAL INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Other Nonoperating Income (Expense)	The components of other income (loss) are as follows: Three months ended Six months ended 2022 2021 2022 2021 Interest income $ 12 $ 14 $ 24 $ 25 Change in value of investments accounted for at fair value (13,419) (435) (16,837) 1,021 Change in value of warrant liabilities — (3,546) — (7,050) Foreign exchange gain 2,345 659 1,132 320 Other (282) 873 (171) 1,202 Other loss $ (11,344) $ (2,435) $ (15,852) $ (4,482)
Schedule of Accounts, Notes, Loans and Financing Receivable	The components of trade and other receivables are as follows: June 30, 2022 December 31, 2021 Trade receivables $ 2,534 $ 1,858 Other 142 1,753 Notes receivable, net 343 343 $ 3,019 $ 3,954
Schedule of Accounts Payable and Accrued Liabilities	The components of accounts payable and accrued liabilities are as follows: June 30, 2022 December 31, 2021 Accounts payable $ 2,159 $ 3,038 Payroll liabilities 465 1,988 Other accrued liabilities 660 738 $ 3,284 $ 5,764

FAIR VALUE ACCOUNTING (Tables)

FAIR VALUE ACCOUNTING (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements, Recurring and Nonrecurring	As of June 30, 2022, the fair values of cash and cash equivalents, restricted cash, short-term deposits, receivables, accounts payable and accrued liabilities approximate their carrying values because of the short-term nature of these instruments. Level 1 Level 2 Level 3 Total Investments at fair value $ 21,043 $ 259 $ — $ 21,302 Marketable equity securities 355 — — 355 Marketable debt securities — 11,440 — 11,440 $ 21,398 $ 11,699 $ — $ 33,097

MARKETABLE SECURITIES - Schedul

MARKETABLE SECURITIES - Schedule of Marketable Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Securities [Abstract]
Cost Basis	$ 11,435
Gross Unrealized Losses	0
Gross Unrealized Gains	5
Fair Value	11,440
Trading Securities, Equity
Cost Basis	756
Gross Unrealized Losses	(401)
Gross Unrealized Gains	0
Fair Value	355
Cost Basis	12,191	$ 756
Gross Unrealized Gains	(401)	(262)
Gross Unrealized Gains	(5)	0
Fair Value	$ 11,795	$ 494

INVENTORIES - Schedule of Inven

INVENTORIES - Schedule of Inventory, Current (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventory [Line Items]
Concentrates and work-in-progress	$ 25,746	$ 27,619
Inventory Of Ore In Stockpiles	241	351
Raw materials and consumables	4,369	4,170
Inventory, net	30,356	32,140
Current	28,565	30,772
Long term - raw materials and consumables	$ 1,791	$ 1,368

PLANT AND EQUIPMENT AND MINER_3

PLANT AND EQUIPMENT AND MINERAL PROPERTIES - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Cost	$ 59,126	$ 57,915
Accumulated Depreciation	(37,611)	(35,932)
Net Book Value	21,515	21,983
Nichols Ranch
Property, Plant and Equipment [Line Items]
Cost	29,210	29,210
Accumulated Depreciation	(19,203)	(18,185)
Net Book Value	10,007	11,025
Alta Mesa
Property, Plant and Equipment [Line Items]
Cost	13,626	13,626
Accumulated Depreciation	(5,451)	(4,996)
Net Book Value	8,175	8,630
Equipment and other
Property, Plant and Equipment [Line Items]
Cost	16,290	15,079
Accumulated Depreciation	(12,957)	(12,751)
Net Book Value	$ 3,333	$ 2,328

PLANT AND EQUIPMENT AND MINER_4

PLANT AND EQUIPMENT AND MINERAL PROPERTIES - Schedule of Summary of Mineral Properties (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Mineral properties	$ 83,539	$ 83,539
Uranerz ISR properties
Property, Plant and Equipment [Line Items]
Mineral properties	25,974	25,974
Sheep Mountain
Property, Plant and Equipment [Line Items]
Mineral properties	34,183	34,183
Roca Honda
Property, Plant and Equipment [Line Items]
Mineral properties	22,095	22,095
Other
Property, Plant and Equipment [Line Items]
Mineral properties	$ 1,287	$ 1,287

PLANT AND EQUIPMENT AND MINER_5

PLANT AND EQUIPMENT AND MINERAL PROPERTIES (Narrative) (Details) $ in Thousands		3 Months Ended		6 Months Ended
	May 19, 2022 USD ($) mi a purchaseAgreement	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)
Property, Plant and Equipment [Abstract]
Depreciation expense		$ 870	$ 790	$ 1,679	$ 1,559
Purchase Agreement, acres to purchase | a	37,300
Purchase Agreement, miles to purchase | mi	58.3
Number of purchase agreements | purchaseAgreement	2
Purchase Agreement, purchase price	$ 27,500
Purchase Agreement, deposit payment	5,500	5,500
Purchase Agreement, payment due at closing	$ 22,000
Purchase Agreement, direct deal costs		$ 500		$ 500

ASSET RETIREMENT OBLIGATIONS _3

ASSET RETIREMENT OBLIGATIONS AND RESTRICTED CASH - Schedule of Change in Asset Retirement Obligation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]
Asset retirement obligation, beginning of period			$ 13,687	$ 13,038	$ 13,038
Revision of estimate			(445)		(235)
Accretion of liabilities	$ 510	$ 351	904	$ 672	1,284
Asset retirement obligation, end of period	14,146		14,146		13,687
Asset Retirement Obligation [Abstract]
Current	219		219		27
Non-current	13,927		13,927		13,660
Asset retirement obligation, end of period	$ 14,146		14,146		13,687
Asset Retirement Obligation, Disposal Of Non-Core Obligations			0		(269)
Asset Retirement Obligation, Liabilities Settled			$ 0		$ (131)

ASSET RETIREMENT OBLIGATIONS _4

ASSET RETIREMENT OBLIGATIONS AND RESTRICTED CASH - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Asset Retirement Obligations [Line Items]
Asset retirement obligation	$ 14,146	$ 13,687	$ 13,038
Minimum
Schedule of Asset Retirement Obligations [Line Items]
Risk Free Rate	9.50%
Inflation rate	2%
Maximum
Schedule of Asset Retirement Obligations [Line Items]
Risk Free Rate	11.67%
Inflation rate	2.41%
Canyon Project
Schedule of Asset Retirement Obligations [Line Items]
Asset retirement obligation	$ 42,910	$ 41,340

ASSET RETIREMENT OBLIGATIONS _5

ASSET RETIREMENT OBLIGATIONS AND RESTRICTED CASH - Schedule of Restricted Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Restricted Cash And Cash Equivalents [Roll Forward]
Restricted cash, beginning of period	$ 20,305	$ 20,817
Additional collateral posted	21	48
Refunds of collateral	0	(560)
Restricted cash, end of period	$ 20,326	$ 20,305

LEASES - Narrative (Details)

LEASES - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Operating Leased Assets [Line Items]
Operating lease right of use asset	$ 271		$ 271		$ 408
Current portion of operating lease liability	312		312		324
Operating lease, liability, noncurrent	0		0		$ 145
Total lease expense	$ 156	$ 158	$ 313	$ 316
Minimum
Operating Leased Assets [Line Items]
Term of contract	11 months		11 months
Maximum
Operating Leased Assets [Line Items]
Renewal term	5 years		5 years

LEASES - Schedule of Lease Cost

LEASES - Schedule of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
Operating leases	$ 77	$ 77	$ 154	$ 154
Short-term leases	79	81	159	162
Total lease expense	$ 156	$ 158	$ 313	$ 316
Weighted average remaining lease term of operating leases	10 months 24 days	1 year 10 months 24 days	10 months 24 days	1 year 10 months 24 days
Weighted average discount rate of operating leases	9%	9%	9%	9%
Cash paid for amounts included in the measurement of operating lease liabilities	$ 87	$ 85	$ 174	$ 170

CAPITAL STOCK - Narrative (Deta

CAPITAL STOCK - Narrative (Details) - At The Market Sale Of Stock shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($) shares
Class of Warrant or Right [Line Items]
Sale of stock, number of shares issued (in shares) | shares	770
Sale of stock, consideration received | $	$ 7,890

BASIC AND DILUTED LOSS PER CO_3

BASIC AND DILUTED LOSS PER COMMON SHARE - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Income (loss) attributable to shareholders, basic	$ (18,054)	$ (10,784)	$ (32,783)	$ (21,692)
Basic weighted average number of common shares outstanding (in shares)	157,491,807	144,450,494	157,044,331	140,923,146
Income (loss) per common share, basic (in dollars per share)	$ (0.11)	$ (0.07)	$ (0.21)	$ (0.15)

BASIC AND DILUTED LOSS PER CO_4

BASIC AND DILUTED LOSS PER COMMON SHARE - Narrative (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Antidilutive securities (in shares)	4,030	6,290

SHARE-BASED PAYMENTS - Narrativ

SHARE-BASED PAYMENTS - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 18, 2022	Jan. 25, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award exercise period					5 years
Exercisable options, weighted average remaining contractual term					1 year 11 months 1 day
Number of grants in period (in shares)	70,000
Grants in period, weighted average exercise price (in dollars per share)					$ 6.50		$ 3.99
Number of options (in shares)			873,067		873,067		942,882		1,609,087
Number of exercisable options (in shares)			721,496		721,496
Outstanding options, weighted average exercise price (in dollars per share)			$ 3.31		$ 3.31		$ 2.79		$ 2.91
Exercisable options, weighted average exercise price (in dollars per share)			$ 2.79		$ 2.79
Options, vested and expected to Vest, aggregate intrinsic value			$ 1,584		$ 1,584
Share-based compensation			$ 1,147	$ 489	$ 2,009	$ 1,190
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term					2 years 4 months 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value					$ 1,160	1,750
Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (in shares)			15,756,942		15,756,942
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		100,000
Award vesting period					2 years
Share-based compensation			$ 109	37	$ 141	$ 240
Unrecognized compensation costs related to unvested stock options					$ 460
Share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition					1 year 6 months 14 days
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		330,000
Award vesting period					3 years
Granted, nonvested, number of shares (in shares)	20,000				350,000	440,000
Grants in period, grant date intrinsic value (in dollars per share)					$ 2,930,000	$ 2,670,000
Share-based compensation			488	390	$ 972	$ 753
Unrecognized compensation costs related to RSU awards					$ 1,820
Share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition					1 year 11 months 15 days
Stock Appreciation Rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		830,000
Award vesting period					5 years			5 years
Number of grants in period (in shares)								2,200,000
Grants in period, weighted average exercise price (in dollars per share)								$ 1.25
Granted, nonvested, number of shares (in shares)					833,315
Share-based compensation			$ 550	$ 62	$ 896	$ 197
Unrecognized compensation costs related to RSU awards					$ 2,300
Share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition					1 year 2 months 19 days
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted	100,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Issued, Number					830,000	0
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable options, weighted average remaining contractual term					10 years
Grants in period, weighted average exercise price (in dollars per share)					$ 10.03		8.41
Outstanding options, weighted average exercise price (in dollars per share)			$ 10.03		10.03		$ 8.41		$ 15.61
Exercisable options, weighted average exercise price (in dollars per share)			$ 7.14		7.14
Share-based Compensation Award, Tranche One | Stock Appreciation Rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period, weighted average exercise price (in dollars per share)					$ 12			$ 5
Period of exercise price					90 days			90 days
Share-based Compensation Award, Tranche Two | Stock Appreciation Rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period, weighted average exercise price (in dollars per share)					$ 14			$ 7
Period of exercise price					90 days			90 days
Share-based Compensation Award, Tranche Three | Stock Appreciation Rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period, weighted average exercise price (in dollars per share)					$ 16			$ 10
Period of exercise price					90 days			90 days
Common Stock | Stock Appreciation Rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period, weighted average exercise price (in dollars per share)					$ 6.47			$ 2.92

SHARE-BASED PAYMENTS - Schedule

SHARE-BASED PAYMENTS - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Employee Stock Option	6 Months Ended
	Jun. 30, 2022 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.34%
Expected life (in years)	3 years 2 months 4 days
Expected volatility(1)	73.01%
Expected dividend yield	0%
Weighted-average grant date fair value (in dollars per share)	$ 5.05

SHARE-BASED PAYMENTS - Schedu_2

SHARE-BASED PAYMENTS - Schedule of Share-based Compensation, Stock Options, Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price, beginning of period (in dollars per share)	$ 2.79	$ 2.91	$ 2.91
Grants in period, weighted average exercise price (in dollars per share)	6.50		3.99
Exercises in period, weighted average exercise price (in dollars per share)	2.45		2.95
Forfeitures in period, weighted average exercise price (in dollars per share)	5.78		3.16
Expirations in period, weighted average exercise price (in dollars per share)	2.35		8.14
Weighted average exercise price, end of period (in dollars per share)	3.31		$ 2.79
Exercisable options, weighted average exercise price (in dollars per share)	$ 2.79
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options, beginning of period (in shares)	942,882	1,609,087	1,609,087
Number of grants in period, net of forfeitures (in shares)	109,328	160,000	169,310
Number of forfeitures in period (in shares)	(3,385)		(8,048)
Number of expirations in period (in shares)	(15,506)		(51,653)
Number of options, end of period (in shares)	873,067		942,882
Number of exercisable options (in shares)	721,496
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	2 years 4 months 2 days
Exercisable options, weighted average remaining contractual term	1 year 11 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$ 1,584
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 1,544
Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	160,252		775,814
Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price, beginning of period (in dollars per share)	$ 1.70	$ 1.70	$ 1.70
Grants in period, weighted average exercise price (in dollars per share)	5.84		3.89
Exercises in period, weighted average exercise price (in dollars per share)	1.70		1.70
Forfeitures in period, weighted average exercise price (in dollars per share)	3.89		1.76
Expirations in period, weighted average exercise price (in dollars per share)			1.70
Weighted average exercise price, end of period (in dollars per share)	1.70		1.70
Exercisable options, weighted average exercise price (in dollars per share)	1.70
Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price, beginning of period (in dollars per share)	8.41	$ 15.61	15.61
Grants in period, weighted average exercise price (in dollars per share)	10.03		8.41
Exercises in period, weighted average exercise price (in dollars per share)	5.18		7.42
Forfeitures in period, weighted average exercise price (in dollars per share)	6.47		5.91
Expirations in period, weighted average exercise price (in dollars per share)			15.61
Weighted average exercise price, end of period (in dollars per share)	10.03		$ 8.41
Exercisable options, weighted average exercise price (in dollars per share)	$ 7.14
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Exercisable options, weighted average remaining contractual term	10 years
Equity Option
Number of Shares
Number of nonvested shares, beginning of period (in shares)	213,317	403,990	403,990
Granted, nonvested, number of shares (in shares)	109,328		169,310
Vested, number of shares (in shares)	(167,689)		(351,934)
Nonvested options forfeited, number of shares (in shares)	(3,385)		(8,049)
Number of nonvested shares, end of period (in shares)	151,571		213,317
Weighted Average Grant Date Fair Value
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share)	$ 1.34	$ 0.94	$ 0.94
Granted, nonvested, weighted average grant date fair value (in dollars per share)	5.05		2.06
Vested, weighted average grant date fair value (in dollars per share)	1.12		1.23
Nonvested options forfeited, weighted average grant date fair value (in dollars per share)	5		1.60
Nonvested, weighted average grant date fair value, end of period (in dollars per share)	$ 4.17		$ 1.34

SHARE-BASED PAYMENTS - Schedu_3

SHARE-BASED PAYMENTS - Schedule of Share-based Compensation, Restricted Stock, Restricted Stock Units Activity and SAR's (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 18, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense		$ 1,147	$ 489	$ 2,009	$ 1,190
Weighted Average Grant Date Fair Value
Common stock, shares, outstanding (in shares)		157,569,420		157,569,420		156,262,199
Common stock, shares, issued (in shares)		157,569,420		157,569,420		156,262,199
Share capital Common shares, without par value, unlimited shares authorized; shares issued and outstanding 157,569,420 at June 30, 2022 and 156,262,199 at December 31, 2021		$ 695,404		$ 695,404		$ 685,903
Equity Option
Weighted Average Grant Date Fair Value
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share)				$ 1.34	$ 0.94	$ 0.94
Nonvested, weighted average grant date fair value, end of period (in dollars per share)		$ 4.17		$ 4.17		$ 1.34
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense		$ 109	37	$ 141	$ 240
Weighted Average Grant Date Fair Value
Unrecognized Compensation Costs Related To Unvested Stock Options				460
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense		$ 488	390	$ 972	$ 753
Number of Shares
Granted, nonvested, number of shares (in shares)	20,000			350,000	440,000
Weighted Average Grant Date Fair Value
Unrecognized Compensation Costs Related To R S U Awards				$ 1,820
Restricted Stock Units (RSUs) | Equity Option
Number of Shares
Number of nonvested shares, beginning of period (in shares)				900,064	1,094,056	1,094,056
Granted, nonvested, number of shares (in shares)				354,406		441,241
Vested, number of shares (in shares)				(518,856)		(635,233)
Forfeited, number of shares (in shares)				(42,082)
Number of nonvested shares, end of period (in shares)		693,532		693,532		900,064
Weighted Average Grant Date Fair Value
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share)				$ 2.94	$ 1.98	$ 1.98
Granted, nonvested, weighted average grant date fair value (in dollars per share)				6.59		3.89
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value				5.34
Vested, weighted average grant date fair value (in dollars per share)				2.93		1.94
Nonvested, weighted average grant date fair value, end of period (in dollars per share)		$ 4.66		$ 4.66		$ 2.94
Stock Appreciation Rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense		$ 550	$ 62	$ 896	$ 197
Number of Shares
Number of nonvested shares, beginning of period (in shares)				1,672,422	1,720,623	1,720,623
Granted, nonvested, number of shares (in shares)				833,315
Exercised, number of shares (in shares)				(6,730)		(48,201)
Forfeited, number of shares (in shares)				(34,921)
Number of nonvested shares, end of period (in shares)		2,464,086		2,464,086		1,672,422
Weighted Average Grant Date Fair Value
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share)				$ 2.92	$ 2.92	$ 2.92
Granted, nonvested, weighted average grant date fair value (in dollars per share)				6.47
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Exercise Price				2.92		2.92
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value				5.79
Nonvested, weighted average grant date fair value, end of period (in dollars per share)		$ 4.08		$ 4.08		$ 2.92
Unrecognized Compensation Costs Related To R S U Awards				$ 2,300
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Number		1,092,143		1,092,143
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Exercise Price		$ 2.92		$ 2.92
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms				2 years 6 months 18 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Remaining Contractual Term				1 year 6 months 21 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding		$ 3,301		$ 3,301
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Aggregate Intrinsic Value		$ 2,173		$ 2,173
Stock Appreciation Rights (SARs) | Equity Option
Number of Shares
Number of nonvested shares, beginning of period (in shares)				573,549	1,720,623	1,720,623
Granted, nonvested, number of shares (in shares)				833,315
Vested, number of shares (in shares)						(1,147,074)
Forfeited, number of shares (in shares)				(34,921)
Number of nonvested shares, end of period (in shares)		1,371,943		1,371,943		573,549
Weighted Average Grant Date Fair Value
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share)				$ 1.19	$ 1.25	$ 1.25
Granted, nonvested, weighted average grant date fair value (in dollars per share)				3.99
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value				4.05
Vested, weighted average grant date fair value (in dollars per share)						1.27
Nonvested, weighted average grant date fair value, end of period (in dollars per share)		$ 2.83		$ 2.83		$ 1.19

SHARE-BASED PAYMENTS - Schedu_4

SHARE-BASED PAYMENTS - Schedule of Share-based Payment, SARs, Valuation Assumptions (Details) - Stock Appreciation Rights (SARs)	6 Months Ended
	Jun. 30, 2022 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.68%
Expected life (in years)	4 years 11 months 23 days
Expected volatility(1)	72.81%
Expected dividend yield	0%
Weighted-average grant date fair value (in dollars per share)	$ 3.99

SUPPLEMENTAL FINANCIAL INFORM_3

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Other Nonoperating Income (Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Interest income	$ 12	$ 14	$ 24	$ 25
Change in value of investments accounted for at fair value	(13,419)	(435)	(16,837)	1,021
Change in value of warrant liabilities	0	(3,546)	0	(7,050)
Foreign exchange gain	2,345	659	1,132	320
Other	(282)	873	(171)	1,202
Other loss	$ (11,344)	$ (2,435)	$ (15,852)	$ (4,482)

SUPPLEMENTAL FINANCIAL INFORM_4

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts payable	$ 2,159	$ 3,038
Payroll liabilities	465	1,988
Other accrued liabilities	660	738
Accounts payable and accrued liabilities (Note 12)	$ 3,284	$ 5,764

SUPPLEMENTAL FINANCIAL INFORM_5

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Trade receivables	$ 2,534	$ 1,858
Other	142	1,753
Notes receivable, net	343	343
Trade and Other Receivables	$ 3,019	$ 3,954

SUPPLEMENTAL FINANCIAL INFORM_6

SUPPLEMENTAL FINANCIAL INFORMATION - Narrative (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Related Party Transaction [Line Items]
Other receivables	$ 1,750
Consolidated Uranium Inc.
Related Party Transaction [Line Items]
Other receivables	$ 1,650

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - (Narrative) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Other Commitments [Line Items]
Asset retirement obligation	$ 14,146	$ 13,687	$ 13,038
Canyon Project
Other Commitments [Line Items]
Loss contingency, estimate of possible loss	20,330	20,310
Asset retirement obligation	$ 42,910	$ 41,340

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)			1 Months Ended	6 Months Ended
	Jun. 01, 2022	Jun. 01, 2020	Jun. 30, 2016	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Jun. 30, 2018
Related Party Transaction [Line Items]
Lessor, Operating Lease, Annual Lease Expense	$ 15,000	$ 12,000
Lessor, Operating Lease, Monthly Lease Payment	$ 1,250	$ 1,000
Royalty percentage of minerals recovered sold under minimum price threshold			3.125%
Mineral price per pound, low range							$ 65
Royalty percentage of minerals recovered sold between price thresholds			6.25%
Mineral price per pound, upper range							$ 95
Royalty percentage of minerals recovered sold above maximum price threshold			7.50%
Accounts Receivable, Related Parties				$ 400,000
Director
Related Party Transaction [Line Items]
Equity method, ownership percentage				81%
Proceeds from Contributed Capital				$ 0	$ 230,000
Director | Leoncito Project, L.L.C.
Related Party Transaction [Line Items]
Testing Permit and Lease Option Agreement, Accrued Liability				$ 220,000		$ 0
United Nuclear | Director
Related Party Transaction [Line Items]
Equity method, ownership percentage				19%

FAIR VALUE ACCOUNTING - Fair Va

FAIR VALUE ACCOUNTING - Fair Value Measurements, Recurring and Nonrecurring (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments at fair value	$ 21,302	$ 38,540
Financial instruments fair value	33,097
Marketable equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments at fair value	355
Marketable debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments at fair value	$ 11,440
Virginia Energy Resources Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage Of Fair Value Investment	14.80%
Consolidated Uranium Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage Of Fair Value Investment	17.90%
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments at fair value	$ 21,043
Financial instruments fair value	21,398
Level 1 | Marketable equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments at fair value	355
Level 1 | Marketable debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments at fair value	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments at fair value	259
Financial instruments fair value	11,699
Level 2 | Marketable equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments at fair value	0
Level 2 | Marketable debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments at fair value	11,440
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments at fair value	0
Financial instruments fair value	0
Level 3 | Marketable equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments at fair value	0
Level 3 | Marketable debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments at fair value	$ 0